Table 4 OAR sparing comparison
From: Feasibility of constant dose rate VMAT in the treatment of nasopharyngeal cancer patients
CDR-VMAT | VDR-VMAT | MCO-VMAT | p | |
|---|---|---|---|---|
Brainstem | ||||
Dmax (Gy) | 54.26 ± 3.21 | 52.19 ± 1.65 | 52.79 ± 4.77 | 0.01 |
Cord | ||||
Dmax(Gy) | 45.12 ± 4.94 | 44.59 ± 2.10 | 44.11 ± 4.37 | 0.47 |
Left parotid | ||||
Dmean (Gy) | 29.72 ± 1.48 | 28.42 ± 1.75 | 28.46 ± 2.70 | 0.93 |
V26 (%) | 53.84 ± 4.41 | 50.55 ± 3.75 | 49.73 ± 8.82 | 0.34 |
V32 (%) | 34.36 ± 5.50 | 33.22 ± 5.28 | 33.01 ± 9.33 | 0.16 |
V50 (%) | 6.44 ± 5.05 | 6.55 ± 5.65 | 5.72 ± 4.58 | 0.68 |
Right parotid | ||||
Dmean (Gy) | 29.79 ± 1.73 | 28.76 ± 1.15 | 28.6 ± 2.18 | 0.98 |
V26 (%) | 48.04 ± 3.90 | 47.38 ± 3.75 | 48.45 ± 7.99 | 0.42 |
V32 (%) | 31.78 ± 5.80 | 30.22 ± 5.35 | 30.84 ± 8.28 | 0.30 |
V50 (%) | 7.07 ± 3.81 | 6.17 ± 3.93 | 6.26 ± 3.34 | 0.45 |